UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
There are countless ways to make additional income. Find the best methods that suit your skills and schedule to enhance your earnings.
17,258 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
If you’re wondering should stock wait dip? on AMD stock, you’re not alone. This guide breaks down whether a pullback ...
SoFi's Galileo platform powers card programs and payments for fintech partners. This article explains why sofi's gali...
The Pentagon is releasing new files on unidentified phenomena, inviting the public to draw their own conclusions. The...
MeridianLink unveils MeridianLink Intelligence within its MeridianLink One platform, introducing the Millie AI agent ...
A wave of healthcare AI players trading under $50 is drawing attention for real progress in partnerships and revenue....
A major investment bank just signaled a powerful vote of confidence in Lilly's GLP-1 strategy. This article breaks do...
The Pennsylvania House approved HB 2186, a by-right ADU reform, in a bipartisan vote and sent the bill to the Senate....
Samsung Electronics is under a developing insider-trading investigation as regulators scrutinize stock moves tied to ...
Australia seals its largest defense export to date with a $1.75 billion radar pact in Canada, expanding Arctic securi...
Pfizer may be sitting on a hidden GLP-1 opportunity. This article breaks down why the company could prove to be an un...
Oracle shares hover near $144 as AI infrastructure demand meets cash-flow headwinds. A rising backlog and lofty reven...